Navigation Links
Oncothyreon announces second quarter 2010 financial results conference call
Date:7/26/2010

SEATTLE, WA, July 26 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) will conduct a conference call to discuss its second quarter 2010 financial results on Thursday, August 5, 2010 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the "Events" page of the "News & Events" section of Oncothyreon's website at www.oncothyreon.com. An archive of the webcast will be available after completion of the discussion and will be posted on the Oncothyreon website.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Oncothyreon announces presentations at upcoming investor conferences in June
2. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
3. Oncothyreon reports full year and fourth quarter 2009 financial results
4. Oncothyreon reports first quarter 2010 financial results
5. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
6. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
7. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
8. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
9. Oncothyreon announces webcast of third quarter 2009 financial results conference call
10. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
11. Oncothyreon to present at Rodman Renshaw Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... San Antonio, Texas (PRWEB) , ... ... ... a new study published on October 5, 2017, in the medical journal, ... demonstrated equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech ... technology sector at their fourth annual Conference where founders, investors, innovative practitioners and ... the ELEVATE pitch competition showcasing early stage digital health and med tech companies. ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):